Document is current
Any future updates will be listed below
-
Authors
Phelan, Rachel https://orcid.org/0000-0001-5252-9991
Im, Annie
Hunter, Rebecca L.
Inamoto, Yoshihiro
Lupo-Stanghellini, Maria Teresa
Rovo, Alicia https://orcid.org/0000-0002-7757-4753
Badawy, Sherif M.
Burns, Linda https://orcid.org/0000-0003-1341-4424
Eissa, Hesham
Murthy, Hemant S.
Prasad, Pinki https://orcid.org/0000-0003-4759-489X
Sharma, Akshay https://orcid.org/0000-0003-3281-2081
Suelzer, Elizabeth https://orcid.org/0000-0002-1809-8080
Agrawal, Vaibhav
Aljurf, Mahmoud https://orcid.org/0000-0003-3942-7370
Baker, Karen
Basak, Grzegorz W. https://orcid.org/0000-0003-3858-8180
Buchbinder, David
DeFilipp, Zachariah https://orcid.org/0000-0002-7994-8974
Grkovic, Lana Desnica
Dias, Ajoy
Einsele, Hermann
Eisenberg, Michael L.
Epperla, Narendranath https://orcid.org/0000-0002-8216-3457
Farhadfar, Nosha
Flatau, Arthur
Gale, Robert Peter
Greinix, Hildegard
Hamilton, Betty K. https://orcid.org/0000-0003-1252-6539
Hashmi, Shahrukh
Hematti, Peiman
Jamani, Kareem
Maharaj, Dipnarine
Murray, John
Naik, Seema https://orcid.org/0000-0002-9859-151X
Nathan, Sunita https://orcid.org/0000-0001-7920-4265
Pavletic, Steven
Peric, Zinaida https://orcid.org/0000-0001-9458-8025
Pulanic, Drazen
Ross, Richard https://orcid.org/0000-0001-9222-9678
Salonia, Andrea
Sanchez-Ortega, Isabel
Savani, Bipin N.
Schechter, Tal
Shah, Ami J.
Smith, Stephanie M.
Snowden, John A.
Steinberg, Amir
Tremblay, Douglas https://orcid.org/0000-0003-2584-6953
Vij, Sarah C.
Walker, Lauren
Wolff, Daniel https://orcid.org/0000-0001-7015-3190
Yared, Jean A. https://orcid.org/0000-0002-5346-6299
Schoemans, Hélène https://orcid.org/0000-0002-7568-8239
Tichelli, André
- License Information
-
More Information
Article History
Received: 18 November 2021
Revised: 10 December 2021
Accepted: 18 January 2022
First Online: 6 May 2022
Competing interests
: HE reports grants and other from BMS/Celgene, grants and other from Janssen, grants and other from Amgen, other from Takeda, grants and other from Sanofi, grants and other from GSK, during the conduct of the study. SH reports other from Pfizer, other from Novartis, other from Therakos, other from Janssen, other from MSD, outside the submitted work. YI reports personal fees from Novartis, personal fees from Janssen, personal fees from Meiji Seika Pharma, outside the submitted work. RP reports research funding from Amgen. RR reports other from Diurnal Plc, during the conduct of the study. HS reports participation in advisory boards for Janssen & Novartis; speaker’s fees from Incyte, Jazz Pharmaceuticals, Takeda, Novartis and the BHS (Belgian Hematological Society); travel grants from EBMT, CIBMTR, Incyte & Gilead and research funding from Novartis & the BHS, outside of the submitted work. AR reports grants from Novartis, grants from CSL Behring, grants from Alexion, personal fees from Novartis, personal fees from BMS, personal fees from OrPha Swiss GmbH, other from Amgen, other from AstraZeneca, other from Sanofi, other from Celgene, outside the submitted work. ASharma reports clinical trial salary support from Vertex Pharmaceuticals, CRISPR Therapeutics, Novartis paid to his institution, and personal consultancy fees from Spotlight Therapeutics, outside the submitted work. JAS reports personal fees from MEDAC, personal fees from KIADIS, personal fees from GILEAD, personal fees from JANSSEN, personal fees from MALLINCKRODT, personal fees from JAZZ, personal fees from ACTELION, outside the submitted work. DW reports grants and personal fees from Novartis, personal fees from Mallinckrodt, personal fees from Behring, outside the submitted work. PG is a consultant to Ascenage Pharma, BeiGene Ltd, Kite Pharma Inc., Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc. and CStone Pharmaceuticals; Medical Director, FFF Enterprises Inc.; Partner, AZCA Inc.; Board of Directors, RakFond Foundation for Cancer Research Support; Scientific Advisory Board, Antegene Biotech LLC and StemRad Ltd.
